CD47-Blocking Antibodies and Atherosclerosis
نویسندگان
چکیده
منابع مشابه
A CD47-blocking TRAIL fusion protein with dual pro-phagocytic and pro-apoptotic anticancer activity.
The expedient removal of dying, damaged or altered cells by phagocytosis is essential for homeostasis. However, cancer cells can evade such phagocytic elimination by cell surfaceupregulation of phagocyte-inhibitory signals, such as CD47. CD47 is a prominent ‘don’t eat me’ signal that binds to signalregulatory protein alpha (SIRPa/SIRPA) expressed on phagocytes (Oldenborg et al, 2001). The CD47-...
متن کاملA function-blocking CD47 antibody suppresses stem cell and EGF signaling in triple-negative breast cancer
CD47 is a signaling receptor for thrombospondin-1 and the counter-receptor for signal-regulatory protein-α (SIRPα). By inducing inhibitory SIRPα signaling, elevated CD47 expression by some cancers prevents macrophage phagocytosis. The anti-human CD47 antibody B6H12 inhibits tumor growth in several xenograft models, presumably by preventing SIRPα engagement. However, CD47 signaling in nontransfo...
متن کاملCD47-blocking therapies stimulate macrophage cytokine secretion and are effective in a model of peritoneal carcinomatosis
Peritoneal carcinomatosis is an advanced state of malignancy often arising from gastrointestinal or ovarian cancers. It is characterized by dissemination of tumors throughout the peritoneal cavity and is associated with 5-year survival rates less than 25%. Since the peritoneal cavity is highly enriched with macrophages, we investigated the efficacy of CD47-blocking therapies for peritoneal carc...
متن کاملSurgical debulking promotes recruitment of macrophages and triggers glioblastoma phagocytosis in combination with CD47 blocking immunotherapy
Surgical resection is a standard component of treatment in the clinical management of patients with glioblastoma multiforme (GBM). However, experimental therapies are rarely investigated in the context of tumor debulking in preclinical models. Here, a surgical debulking GBM xenograft model was developed in nude rats, and was used in combination with CD47 blocking immunotherapy, a novel treatmen...
متن کاملCheckpoint blocking antibodies in cancer immunotherapy.
Cancers can be recognized by the immune system, and the immune system may regulate and even eliminate tumors. The development of checkpoint blocking antibodies, such as those directed against cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed death 1 receptor (PD-1), have demonstrated significant recent promise in the treatment of an expanding list of malignancies. While both CTLA-4 and P...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: JACC: Basic to Translational Science
سال: 2016
ISSN: 2452-302X
DOI: 10.1016/j.jacbts.2016.07.005